PACIFICA Phase 3
Research payments
$576,870
Through program year 2023, $576,870 in research payments was reported against PACIFICA Phase 3, across 66 payments, paid by CTI BioPharma Corp..
- Paid by
- CTI BioPharma Corp.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $224,893 | 31 |
| 2022 | Research | $351,977 | 35 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Abdulraheem Yacoub Kansas City, KS Named on 10 payments
- Grzegorz Obara Las Vegas, NV Named on 5 payments
- Tania Jain Baltimore, MD Named on 5 payments
- Jeanne Palmer Phoenix, AZ Named on 4 payments
- Ian Flinn Nashville, TN Named on 4 payments
- Pankit Vachhani Birmingham, AL Named on 3 payments
- Sarah Wall Columbus, OH Named on 3 payments
- Yousuf Gaffar Columbia, MD Named on 3 payments
- Ronan Swords Portland, OR Named on 3 payments
- James Rossetti Pittsburgh, PA Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.